Study Purpose
This review aims to discuss whether or not the CYD-TDV is a viable preventive measure for Dengue through a systematic review . The objective of this systematic review is to assess the efficacy ( in terms of immunogenicity ) and safety ( in terms of reactogenicity ) of the newly developed CYD-TDV .
2 . Research Methodology 2.1 . Search Strategies
A comprehensive literature search was conducted in October 2016 using the databases PubMed , The Cochrane Library , Scopus , ProQuest , EBSCOhost , and ScienceDirect . The combinations of terms used for the search included “ T etravalent Dengue V accine ”, “ CYD-TDV ”, “ children ”, and “ immunogenicity ”. Where applicable and available , appropriate advance search techniques were applied to narrow the search .
2.2 . Selection of Trials
Inclusion Criteria : Randomized , controlled clinical trial studies Subjects aged 2 to 18 years old Use of the 3-dose CYD-TDV regimen as an intervention Humoral immunogenicity and safety of CYD-TDV as outcomes Exclusion Criteria :
Studies involving subjects of all age groups ( children and adults ) in the same treatment group
Studies that do not measure baseline characteristics of patients 2.3 . Data Extraction The following data was extracted from the studies :
1 . Geometric Mean Titers of neutralizing antibodies against DENV 1 , DENV 2 , DENV 3 , and DENV 4 at baseline and after each dose of CYD-TDV and Control ( Immunogenicity as a measure of efficacy )
2 . Adverse reactions and safety profile of CYD-TDV and Control injections
3 . Study Design : Population characteristics ( Age , Region , Sample size , Baseline Seropositivity *), Intervention , Control , and Outcome measurements .
* Baseline seropositivity refers to the percentage of the population that has antibody titers ≥ 10 1 / dil for any one of the four dengue serologies ( measured using Plaque Reduction Neutralization Test )